[{"id":"c72ecd8f-9c23-45c8-aceb-c2281207ef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT07141771","created_at":"2025-08-30T13:51:58.696Z","updated_at":"2025-08-30T13:51:58.696Z","phase":"Phase 1/2","brief_title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","source_id_and_acronym":"NCT07141771","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • etoposide IV • irinotecan • topotecan • AiRuiYi (fluzoparib) • Zepzelca (lurbinectedin) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-26"},{"id":"bf338af6-7bdc-4263-a249-2470acc07fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06860529","created_at":"2025-06-07T14:59:59.699Z","updated_at":"2025-06-07T14:59:59.699Z","phase":"Phase 2","brief_title":"Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06860529","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 357","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-03-06"},{"id":"cd1a66a4-5dbf-4a32-901c-c7c94f2f942d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06576921","created_at":"2025-02-26T06:54:16.281Z","updated_at":"2025-02-26T06:54:16.281Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","source_id_and_acronym":"NCT06576921","lead_sponsor":"Xijing Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • oxaliplatin • Hetronifly (serplulimab) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-01-13"},{"id":"456efb5b-1647-4ddb-add1-645fa0cf138f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06542588","created_at":"2025-02-26T07:12:34.732Z","updated_at":"2025-02-26T07:12:34.732Z","phase":"Phase 2","brief_title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","source_id_and_acronym":"NCT06542588","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-18"},{"id":"17e8ba18-b2fc-4fc4-a9e2-96bb597a8a60","acronym":"ASTRUM-015","url":"https://clinicaltrials.gov/study/NCT04547166","created_at":"2021-01-18T21:45:04.951Z","updated_at":"2025-02-25T13:48:56.719Z","phase":"Phase 2/3","brief_title":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT04547166 - ASTRUM-015","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • capecitabine • oxaliplatin • Hetronifly (serplulimab) • Hanbeitai (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 568","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 09/24/2025","primary_completion_date":" 09/24/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-10-17"},{"id":"4f96feb5-50d1-43c3-856c-1a2c5c1c2a65","acronym":"ESCC","url":"https://clinicaltrials.gov/study/NCT06601309","created_at":"2025-02-26T07:12:45.028Z","updated_at":"2025-02-26T07:12:45.028Z","phase":"Phase 2","brief_title":"Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC","source_id_and_acronym":"NCT06601309 - ESCC","lead_sponsor":"Fujian Medical University Union Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/11/2024","start_date":" 07/11/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-19"},{"id":"b350213a-f11c-41fb-9ec3-ae6707ff0878","acronym":"ASTRUM-IUmCRC","url":"https://clinicaltrials.gov/study/NCT06491355","created_at":"2025-02-26T07:12:23.836Z","updated_at":"2025-02-26T07:12:23.836Z","phase":"Phase 2","brief_title":"First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06491355 - ASTRUM-IUmCRC","lead_sponsor":"Sir Run Run Shaw Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-07-09"},{"id":"d2eab13c-3e7c-4257-8119-cdbb100f01e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05483530","created_at":"2022-08-02T13:55:16.496Z","updated_at":"2024-07-02T16:35:09.508Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05483530","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • HLX60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-04-16"},{"id":"ba6ca0bb-d657-44f7-92ca-7acf5698ae26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05975749","created_at":"2023-08-04T17:09:49.373Z","updated_at":"2024-07-02T16:35:15.206Z","phase":"Phase 2","brief_title":"Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer","source_id_and_acronym":"NCT05975749","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2024-03-12"},{"id":"da5c6c73-c5e1-4ec2-961a-7a3ca5b0d595","acronym":"","url":"https://clinicaltrials.gov/study/NCT06280495","created_at":"2024-02-28T18:32:13.714Z","updated_at":"2024-07-02T16:35:16.678Z","phase":"Phase 2/3","brief_title":"Neoadjuvant Serplulimab \u0026 Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","source_id_and_acronym":"NCT06280495","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-04"},{"id":"50f25c11-a244-4d2a-bdb8-3cc4a30a5d57","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957510","created_at":"2023-07-24T15:08:42.826Z","updated_at":"2024-07-02T16:35:18.051Z","phase":"Phase 2","brief_title":"Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment","source_id_and_acronym":"NCT05957510","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • etoposide IV • Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-22"},{"id":"59cf1c76-20c0-482d-a704-e18624a0a2cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787613","created_at":"2023-03-28T14:05:08.783Z","updated_at":"2024-07-02T16:35:18.055Z","phase":"Phase 2","brief_title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","source_id_and_acronym":"NCT05787613","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • ROS1 • LAG3","pipe":" | ","alterations":" PD-L1 expression • ROS1 rearrangement • LAG3 expression","tags":["PD-L1 • ROS1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ROS1 rearrangement • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-02-22"},{"id":"da311a09-c528-4f05-95fc-0dd180af7950","acronym":"","url":"https://clinicaltrials.gov/study/NCT05400265","created_at":"2022-06-01T14:58:52.168Z","updated_at":"2024-07-02T16:35:20.637Z","phase":"Phase 1","brief_title":"Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor","source_id_and_acronym":"NCT05400265","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • HLX26"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2024-02-06"},{"id":"be9703ab-38ce-4bf6-9235-5a6bc13410bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06099951","created_at":"2023-10-25T19:14:07.301Z","updated_at":"2024-07-02T16:35:31.736Z","phase":"Phase 2","brief_title":"Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy","source_id_and_acronym":"NCT06099951","lead_sponsor":"Sun Yat-sen University","biomarkers":" MSH6 • MSH2","pipe":"","alterations":" ","tags":["MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-10-25"},{"id":"a814061c-a9d2-4cbb-9eda-0e4a4d034755","acronym":"","url":"https://clinicaltrials.gov/study/NCT05584137","created_at":"2022-10-18T14:57:08.195Z","updated_at":"2024-07-02T16:35:40.262Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC","source_id_and_acronym":"NCT05584137","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • HLX26"],"overall_status":"Suspended","enrollment":" Enrollment 49","initiation":"Initiation: 06/15/2023","start_date":" 06/15/2023","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-08-11"},{"id":"2f7123d3-059b-467b-a21a-258e54ebdc19","acronym":"","url":"https://clinicaltrials.gov/study/NCT04297995","created_at":"2021-01-18T20:51:01.364Z","updated_at":"2024-07-02T16:35:40.677Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors","source_id_and_acronym":"NCT04297995","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-08"},{"id":"945fc964-91d3-4c6f-99ff-258f22b03b86","acronym":"ASTRUM-004","url":"https://clinicaltrials.gov/study/NCT04033354","created_at":"2021-01-18T19:47:42.168Z","updated_at":"2024-07-02T16:35:40.664Z","phase":"Phase 3","brief_title":"A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC","source_id_and_acronym":"NCT04033354 - ASTRUM-004","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • ROS1","pipe":"","alterations":" ","tags":["PD-L1 • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 08/14/2019","start_date":" 08/14/2019","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-08-08"},{"id":"97633adb-6d2e-4686-b967-d9468938de97","acronym":"HLX10-002-NSCLC301","url":"https://clinicaltrials.gov/study/NCT03952403","created_at":"2021-01-18T19:27:10.739Z","updated_at":"2025-02-25T13:48:42.589Z","phase":"Phase 3","brief_title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03952403 - HLX10-002-NSCLC301","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • ALK • TMB • MSI • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["PD-L1 • ALK • TMB • MSI • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Hetronifly (serplulimab) • Hanbeitai (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 643","initiation":"Initiation: 12/02/2019","start_date":" 12/02/2019","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 03/15/2024","study_completion_date":" 03/15/2024","last_update_posted":"2023-08-08"},{"id":"6e4b55ea-6316-4cd0-bc08-8e0da9b09848","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954429","created_at":"2023-07-20T23:10:54.535Z","updated_at":"2024-07-02T16:35:42.486Z","phase":"Phase 2","brief_title":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study","source_id_and_acronym":"NCT05954429","lead_sponsor":"Junjie Peng","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" BRAF mutation • RAS wild-type","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-07-20"},{"id":"8a38e0cd-a975-482e-8cc1-cd10a578e9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942573","created_at":"2023-07-12T15:08:58.809Z","updated_at":"2024-07-02T16:35:43.331Z","phase":"Phase 2","brief_title":"Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial","source_id_and_acronym":"NCT05942573","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 12/24/2022","start_date":" 12/24/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-12"},{"id":"5367767c-20f4-47de-89d7-b04775dc10be","acronym":"SNACRT","url":"https://clinicaltrials.gov/study/NCT05918419","created_at":"2023-06-26T14:09:10.604Z","updated_at":"2024-07-02T16:35:44.754Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction","source_id_and_acronym":"NCT05918419 - SNACRT","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-06-26"},{"id":"a99ff0ae-3072-46f7-b44c-8b00b9ce5974","acronym":"ASTRUM-007","url":"https://clinicaltrials.gov/study/NCT03958890","created_at":"2021-01-18T19:28:52.985Z","updated_at":"2024-07-02T16:35:50.253Z","phase":"Phase 3","brief_title":"A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)","source_id_and_acronym":"NCT03958890 - ASTRUM-007","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • Hetronifly (serplulimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 489","initiation":"Initiation: 06/19/2019","start_date":" 06/19/2019","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-04-18"},{"id":"5450c8f1-79ea-4dc3-b6b6-f33328de0832","acronym":"","url":"https://clinicaltrials.gov/study/NCT05641493","created_at":"2022-12-07T15:57:22.785Z","updated_at":"2024-07-02T16:35:50.973Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation","source_id_and_acronym":"NCT05641493","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • BRAF V600","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • RX208"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 03/04/2025","primary_completion_date":" 03/04/2025","study_txt":" Completion: 02/27/2026","study_completion_date":" 02/27/2026","last_update_posted":"2023-04-10"},{"id":"40e0b032-116e-47aa-8c4a-24a6a09143af","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769725","created_at":"2023-03-15T14:02:25.080Z","updated_at":"2024-07-02T16:35:53.234Z","phase":"Phase 2","brief_title":"A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer","source_id_and_acronym":"NCT05769725","lead_sponsor":"RenJi Hospital","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Hetronifly (serplulimab) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-03-15"}]